银屑病
促炎细胞因子
白细胞介素23
医学
肿瘤坏死因子α
免疫学
发病机制
单克隆抗体
免疫系统
白细胞介素17
抗体
炎症
作者
Uyen Ngoc Mui,Ravi R Patel,Ramya Vangipuram,Stephen K. Tyring
出处
期刊:PubMed
日期:2019-11-01
卷期号:24 (6): 1-4
被引量:2
摘要
Psoriasis is an immune-mediated inflammatory skin condition associated with many comorbidities and poor quality of life. The pathogenesis of psoriasis is complex and involves numerous proinflammatory cytokines. Many biologic therapies have been developed to block the action of these proinflammatory molecules, including inhibitors of tumor necrosis factor (TNF), interleukin (IL)-17, IL-12, and IL-23. IL-23 is composed of two subunits, p19 and p40. The p40 subunit is shared with IL-12, and inhibitors of the p40 subunit can block both IL-12 and IL-23 signaling. Recent advances in the understanding of psoriasis, however, have shown IL-23 to be more important than IL-12 in the pathogenesis of psoriasis. This has led to the development of IL-23p19 antagonists, the newest class of biologics for psoriasis. Here, we will discuss the safety and efficacy of tildrakizumab, a monoclonal antibody targeting IL-23p19.
科研通智能强力驱动
Strongly Powered by AbleSci AI